CGS-27023

CGS-27023 (also known as CGS 27023A or MMI270) is a potent, non-peptidic, orally active small molecule inhibitor of matrix metalloproteinases (MMPs), particularly targeting stromelysin (MMP3), gelatinase A (MMP2), gelatinase B (MMP9), and neutrophil collagenase (MMP8). It was developed as an experimental agent to block cartilage degradation in preclinical models of arthritis and has been studied for its ability to inhibit the breakdown of extracellular matrix components. The compound acts by binding to the catalytic domain of these enzymes, thereby preventing their proteolytic activity. Its primary use has been in research settings rather than clinical development[3][4][5][6][8].

Other names

161314-70-1161314-82-5MMI270B free baseMMI-270B free baseMMI 270B free base